Edesa Biotech Inc.

1.86
-0.07 (-3.58%)
At close: Feb 11, 2025, 3:39 PM
1.86
0.00%
After-hours Feb 11, 2025, 07:44 PM EST
undefined%
Bid 1.86
Market Cap 6.45M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.93
PE Ratio (ttm) -0.96
Forward PE n/a
Analyst Buy
Ask 2.02
Volume 29,775
Avg. Volume (20D) 26,710
Open 1.94
Previous Close 1.93
Day's Range 1.85 - 2.02
52-Week Range 1.55 - 5.99
Beta undefined

About EDSA

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chro...

Industry Biotechnology
Sector Healthcare
IPO Date Jun 21, 2010
Employees 16
Stock Exchange NASDAQ
Ticker Symbol EDSA

Analyst Forecast

According to 1 analyst ratings, the average rating for EDSA stock is "Buy." The 12-month stock price forecast is $21, which is an increase of 1028.61% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts